Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism

Fig. 6

HDAC inhibitor ITF2357 represses Rad51 expression by inhibiting HDAC2 and upregulating miR-130a-3p. A The potential binding sites between miR-130a-3p and Rad51 predicted by the Targetscan website. B Dual luciferase reporter gene assay to detect the targeting relationship between miR-130a-3p and Rad51. C RIP assay to detect the interaction between miR-130a-3p and Rad51. D RNA pull-down assay to detect the interaction between miR-130a-3p and Rad51. E RT-qPCR to detect the gene expression levels of HDAC2, miR-130a-3p and Rad51. F The protein expression levels of HDAC2 and Rad51 in cells upon different treatments were detected by Western blot. **p < 0.01. ***p < 0.001. ****p < 0.0001. Data between two groups were compared by unpaired t test, and those among multiple groups by one-way ANOVA, followed by Tukey’s post hoc tests. Cellular experiments were repeated three times

Back to article page